Comment from Biocom
AnonymousSupportTrade association
Summary: Biocom, a trade association representing California's life science sector, supports the FDA's draft guidance on using a plausible mechanism framework for individualized therapies. They advocate for further clarification on patient population scope, nonclinical and clinical data requirements, and the streamlining of CMC requirements for advanced therapies.
See attached file(s)